Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults

Idalia M. Gonzalez, Ruth A Karron, Maryna Eichelberger, Edward E. Walsh, Vincent W. Delagarza, Richard G Bennett, Robert M. Chanock, Brian R. Murphy, Mary Lou Clements-Mann, Ann R. Falsey

Research output: Contribution to journalArticle

Abstract

The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive (cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential (cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22% of young subjects and in 16% of elderly subjects. Of those with low levels of RSV neut Ab (titer <9), 10/12 (83% of) young subjects and six/eight (75% of) elderly subjects had a ≥four fold rise in neut Ab titer. Young and elderly subjects immunized simultaneously had similar serum IgG and IgA postimmunization titers to RSV F (IgG, 16.4 vs 16.2, IgA 11.6 vs 12.5, respectively) as did those who were immunized sequentially (IgG 17.4 vs 17.0, IgA 13.0 vs 13.5). In both age groups, sequential immunization elicited higher postimmunization RSV F IgG and IgA titers than simultaneous immunization. Further studies that combine the PFP-2 subunit vaccine with a less attenuated RSV vaccine should be performed. (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)1763-1772
Number of pages10
JournalVaccine
Volume18
Issue number17
DOIs
StatePublished - Mar 6 2000

Fingerprint

Respiratory Syncytial Virus Vaccines
Subunit Vaccines
Respiratory Syncytial Viruses
young adults
Young Adult
Immunoglobulin A
vaccines
viruses
Immunoglobulin G
Neutralizing Antibodies
Vaccines
neutralizing antibodies
temperature
varespladib methyl
Immunization
Attenuated Vaccines
immunization
Volunteers
Glycoproteins
Appointments and Schedules

Keywords

  • Adults
  • Elderly
  • Respiratory syncytial virus vaccines

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. / Gonzalez, Idalia M.; Karron, Ruth A; Eichelberger, Maryna; Walsh, Edward E.; Delagarza, Vincent W.; Bennett, Richard G; Chanock, Robert M.; Murphy, Brian R.; Clements-Mann, Mary Lou; Falsey, Ann R.

In: Vaccine, Vol. 18, No. 17, 06.03.2000, p. 1763-1772.

Research output: Contribution to journalArticle

Gonzalez, IM, Karron, RA, Eichelberger, M, Walsh, EE, Delagarza, VW, Bennett, RG, Chanock, RM, Murphy, BR, Clements-Mann, ML & Falsey, AR 2000, 'Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults', Vaccine, vol. 18, no. 17, pp. 1763-1772. https://doi.org/10.1016/S0264-410X(99)00527-7
Gonzalez, Idalia M. ; Karron, Ruth A ; Eichelberger, Maryna ; Walsh, Edward E. ; Delagarza, Vincent W. ; Bennett, Richard G ; Chanock, Robert M. ; Murphy, Brian R. ; Clements-Mann, Mary Lou ; Falsey, Ann R. / Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. In: Vaccine. 2000 ; Vol. 18, No. 17. pp. 1763-1772.
@article{81b440cfcb834c3eafcc5405320d47cb,
title = "Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults",
abstract = "The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive (cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential (cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22{\%} of young subjects and in 16{\%} of elderly subjects. Of those with low levels of RSV neut Ab (titer <9), 10/12 (83{\%} of) young subjects and six/eight (75{\%} of) elderly subjects had a ≥four fold rise in neut Ab titer. Young and elderly subjects immunized simultaneously had similar serum IgG and IgA postimmunization titers to RSV F (IgG, 16.4 vs 16.2, IgA 11.6 vs 12.5, respectively) as did those who were immunized sequentially (IgG 17.4 vs 17.0, IgA 13.0 vs 13.5). In both age groups, sequential immunization elicited higher postimmunization RSV F IgG and IgA titers than simultaneous immunization. Further studies that combine the PFP-2 subunit vaccine with a less attenuated RSV vaccine should be performed. (C) 2000 Elsevier Science Ltd.",
keywords = "Adults, Elderly, Respiratory syncytial virus vaccines",
author = "Gonzalez, {Idalia M.} and Karron, {Ruth A} and Maryna Eichelberger and Walsh, {Edward E.} and Delagarza, {Vincent W.} and Bennett, {Richard G} and Chanock, {Robert M.} and Murphy, {Brian R.} and Clements-Mann, {Mary Lou} and Falsey, {Ann R.}",
year = "2000",
month = "3",
day = "6",
doi = "10.1016/S0264-410X(99)00527-7",
language = "English (US)",
volume = "18",
pages = "1763--1772",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "17",

}

TY - JOUR

T1 - Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults

AU - Gonzalez, Idalia M.

AU - Karron, Ruth A

AU - Eichelberger, Maryna

AU - Walsh, Edward E.

AU - Delagarza, Vincent W.

AU - Bennett, Richard G

AU - Chanock, Robert M.

AU - Murphy, Brian R.

AU - Clements-Mann, Mary Lou

AU - Falsey, Ann R.

PY - 2000/3/6

Y1 - 2000/3/6

N2 - The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive (cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential (cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22% of young subjects and in 16% of elderly subjects. Of those with low levels of RSV neut Ab (titer <9), 10/12 (83% of) young subjects and six/eight (75% of) elderly subjects had a ≥four fold rise in neut Ab titer. Young and elderly subjects immunized simultaneously had similar serum IgG and IgA postimmunization titers to RSV F (IgG, 16.4 vs 16.2, IgA 11.6 vs 12.5, respectively) as did those who were immunized sequentially (IgG 17.4 vs 17.0, IgA 13.0 vs 13.5). In both age groups, sequential immunization elicited higher postimmunization RSV F IgG and IgA titers than simultaneous immunization. Further studies that combine the PFP-2 subunit vaccine with a less attenuated RSV vaccine should be performed. (C) 2000 Elsevier Science Ltd.

AB - The safety and immunogenicity of the live attenuated cold-passaged, temperature-sensitive (cpts) 248/404 respiratory syncytial virus (RSV) A2 and the RSV A2 purified F glycoprotein (PFP-2) vaccine candidates were evaluated in a placebo-controlled trial in 60 healthy young adults and 60 healthy elderly subjects using simultaneous and sequential (cpts 248/404 followed by PFP-2) vaccination schedules. Both vaccines were well tolerated. The cpts 248/404 vaccine was moderately infectious in both young and old volunteers, but was highly restricted in replication in those who were infected. After both vaccines, RSV neutralizing antibody (neut Ab) titers increased fourfold in 22% of young subjects and in 16% of elderly subjects. Of those with low levels of RSV neut Ab (titer <9), 10/12 (83% of) young subjects and six/eight (75% of) elderly subjects had a ≥four fold rise in neut Ab titer. Young and elderly subjects immunized simultaneously had similar serum IgG and IgA postimmunization titers to RSV F (IgG, 16.4 vs 16.2, IgA 11.6 vs 12.5, respectively) as did those who were immunized sequentially (IgG 17.4 vs 17.0, IgA 13.0 vs 13.5). In both age groups, sequential immunization elicited higher postimmunization RSV F IgG and IgA titers than simultaneous immunization. Further studies that combine the PFP-2 subunit vaccine with a less attenuated RSV vaccine should be performed. (C) 2000 Elsevier Science Ltd.

KW - Adults

KW - Elderly

KW - Respiratory syncytial virus vaccines

UR - http://www.scopus.com/inward/record.url?scp=0033997580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033997580&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00527-7

DO - 10.1016/S0264-410X(99)00527-7

M3 - Article

C2 - 10699324

AN - SCOPUS:0033997580

VL - 18

SP - 1763

EP - 1772

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17

ER -